64 reports of this reaction
3.1% of all CARBOPROST TROMETHAMINE reports
#8 most reported adverse reaction
DYSPNOEA is the #8 most commonly reported adverse reaction for CARBOPROST TROMETHAMINE, manufactured by Pharmacia & Upjohn Company LLC. There are 64 FDA adverse event reports linking CARBOPROST TROMETHAMINE to DYSPNOEA. This represents approximately 3.1% of all 2,057 adverse event reports for this drug.
Patients taking CARBOPROST TROMETHAMINE who experience dyspnoea should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DYSPNOEA is moderately reported among CARBOPROST TROMETHAMINE users, representing a notable but not dominant share of adverse events.
In addition to dyspnoea, the following adverse reactions have been reported for CARBOPROST TROMETHAMINE:
The following drugs have also been linked to dyspnoea in FDA adverse event reports:
DYSPNOEA has been reported as an adverse event in 64 FDA reports for CARBOPROST TROMETHAMINE. This does not prove causation, but indicates an association observed in post-market surveillance data.
DYSPNOEA accounts for approximately 3.1% of all adverse event reports for CARBOPROST TROMETHAMINE, making it a notable side effect.
If you experience dyspnoea while taking CARBOPROST TROMETHAMINE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.